Date: Monday, November 9, 2015
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Several vitamin D receptor (VDR) polymorphisms have been associated with cardiovascular (CV) and autoimmune diseases. Carotid plaques are surrogate markers of severe atherosclerotic disease. Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with an increased risk of CV death, mainly due to a process of accelerated atherogenesis. Patients with RA have increased frequency of carotid plaques when compared with the general population. The aim of the present study was to determine the potential association of TaqI (rs731236), ApaI (rs7975232), BsmI (rs1544410) and Fokl (rs2228570) VDR polymorphisms with carotid plaques in patients with RA.
Methods: A total of 591 RA patients from Northern Spain who met the 1987 American College of Rheumatology (ACR) and the 2010 ACR/European League Against Rheumatism criteria for RA were genotyped for rs731236, rs7975232, rs1544410 and rs2228570 VDR polymorphisms by TaqMan genotyping assays. In addition, the presence of carotid plaques was evaluated in these patients by carotid ultrasound technology.
Results: RA patients carrying VDR rs7975232 CC genotype had a decreased risk of carotid plaques, after adjustment for sex, age and traditional CV risk factors (p=0.014, OR=0.46, 95% CI: [0.24-0.85]). This effect was also found in patients who carried the mutant VDR rs7975232 C allele, after adjustment for potential confounder factors (p=0.018, OR=0.70, 95% CI: [0.52-0.94]). Although no association between rs731236, rs1544410 and rs2228570 VDR polymorphisms and presence of carotid plaques was observed, RA patients who carried the GATG haplotype (which harbors the A allele of rs7975232) had an increased risk of carotid plaques, after adjustment for sex, age and traditional CV risk factors (p=0.003, OR=2.20, 95% CI: [1.30-3.73]).
Conclusion: Our results show a protective effect of the VDR rs7975232 allele C on the risk of severe atherosclerosis in patients with RA.
This study was supported by European Union FEDER funds and “Fondo de Investigación Sanitaria” (grant PI12/00060) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain). It was also partially supported by RETICS Programs RD12/0009 (RIER) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain), and in part by grants from the European IMI BTCure Program. RLM is a recipient of a Sara Borrell postdoctoral fellowship from the Instituto Carlos III de Salud at the Spanish Ministry of Health (Spain) (CD12/00425). FG and BU are supported by funds from the RETICS Program (RIER) (RD12/0009/0013).
To cite this abstract in AMA style:López-Mejías R, Genre F, Remuzgo-Martínez S, Robledo G, Ubilla B, Mijares V, Llorca J, Robustillo-Villarino M, Corrales A, González-Juanatey C, Miranda-Filloy JA, Pina T, Blanco R, Vicente E, Alegre JJ, Magro C, Raya E, Tejera B, Ramírez Huaranga MA, Ferraz-Amaro I, Castañeda S, Martín J, Gonzalez-Gay MA. Protective Role of the Vitamin D Receptor Apai (rs7975232) Polymorphism Against Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis from Northern Spain [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/protective-role-of-the-vitamin-d-receptor-apai-rs7975232-polymorphism-against-subclinical-atherosclerosis-in-patients-with-rheumatoid-arthritis-from-northern-spain/. Accessed May 17, 2022.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/protective-role-of-the-vitamin-d-receptor-apai-rs7975232-polymorphism-against-subclinical-atherosclerosis-in-patients-with-rheumatoid-arthritis-from-northern-spain/